Drug Database
TE

terbinafine hydrochloride (MOB015B / MOB 015 / MOB015)

✓ Approved

DongKoo Bio & Pharma · SQLE · Small Molecule

What is terbinafine hydrochloride?

terbinafine hydrochloride is a small molecule developed by DongKoo Bio & Pharma. It is approved for therapeutic indications via topical.

Drug Profile

Brand NamesMOB015B, MOB 015, MOB015
CompanyDongKoo Bio & Pharma
Drug ClassSmall Molecule
Molecular TargetSQLE
RouteTopical
StatusApproved
Sources: ClinicalTrials.gov, DongKoo Bio & Pharma

Mechanism of Action

Molecular Targets

terbinafine hydrochloride acts on 1 molecular target:

SQLEsqualene epoxidase ()
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

terbinafine hydrochloride is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsOnychomycosis✓ Approved

Related Research Articles

PubMedThe American journal of tropical medicine and hygiene2026-07-17

Eyelid Verrucous Sporotrichosis Caused by Sporothrix Brasiliensis Mimicking Cutaneous Leishmaniasis and Complicated by Drug-Drug Interaction.

Rodrigues Felipe Tavares FT, Dos Santos Amanda Ribeiro AR, de Almeida Sandro Rogério SR, Albuquerque Renata Chaves RC et al.

Sporotrichosis caused by Sporothrix brasiliensis is endemic in Brazil and may present with atypical clinical features. We report a case of verrucous sporotrichosis of the eyelid mimicking cutaneous leishmaniasis in a 28-year-old woman without cat exposure or trauma. Initial diagnostic studies were inconclusive, and prolonged treatment with oral itraconazole failed. Subsequent fungal culture and polymerase chain reaction established the diagnosis. Medication review revealed concomitant pantoprazole use, likely impairing itraconazole absorption through pH-dependent bioavailability. Lesion resolution occurred after a 3-month course of oral terbinafine. This case highlights two critical considerations: sporotrichosis should remain in the differential diagnosis of chronic verrucous lesions in endemic regions, and careful evaluation of drug-drug interactions is essential to prevent antifungal treatment failure.

PMID 42462702
Read full article →
PubMedJournal of virology2026-07-17

Cyclo-C stabilizes PEX13 to inhibit porcine epidemic diarrhea virus replication by blocking pexophagy-mediated disruption of antiviral innate immunity.

Lou Jinxiu J, Guo Zhiwei Z, Chen Kang K, Tian Yuanmingyue Y et al.

The persistent threat of porcine epidemic diarrhea virus (PEDV) to the global swine industry is compounded by high neonatal piglet mortality and the absence of effective antiviral therapies. Host-directed strategies that reinforce immunity offer a promising avenue to counter viral immune evasion. Through screening of an FDA-approved compound library, we identify the small-molecule cyclocytidine hydrochloride (Cyclo-C) as a potent inhibitor of PEDV replication that acts by stabilizing the peroxisomal biogenesis factor PEX13, a previously unrecognized host restriction factor. The antiviral activity of Cyclo-C is strictly PEX13-dependent, as it is completely abrogated in PEX13 knockout cells. Mechanistically, Cyclo-C disrupts the interaction between PEX13 and the viral nonstructural protein 8 (NSP8), thereby preventing NSP8-mediated PEX13 degradation and the subsequent induction of PI3K/AKT/mTOR-driven pexophagy. Preservation of peroxisomal integrity stabilizes the peroxisome-localized pool of MAVS, leading to a robust enhancement of type III interferon (IFN-III) responses that suppress viral replication. Critically, this mechanism translates in vivo, where Cyclo-C treatment of PEDV-challenged piglets significantly reduces mortality, lowers viral loads, and protects intestinal villus architecture. Our findings establish Cyclo-C as a first-in-class host-directed therapeutic candidate and validate the concept that pharmacological preservation of peroxisome-mediated innate immunity represents an effective antiviral strategy against enteric coronaviruses. The high genetic variability of porcine epidemic diarrhea virus (PEDV) limits current vaccine efficacy, and no antiviral therapeutics exist. Host-directed therapies targeting cellular pathways that viruses exploit for immune evasion offer an alternative approach. Here, we identify the FDA-approved compound Cyclo-C as a potent inhibitor of PEDV replication. Cyclo-C acts by stabilizing PEX13, a host protein that the virus degrades to evade immunity. By blocking viral protein NSP8 from binding PEX13, Cyclo-C prevents virus-induced pexophagy, thereby preserving peroxisomal integrity. This preserves peroxisome-localized MAVS and enhances type III interferon responses. In infected neonatal piglets, Cyclo-C reduced mortality and viral loads while protecting intestinal integrity. This study provides proof of concept that targeting peroxisomal immune regulation is a viable antiviral strategy and identifies Cyclo-C as a promising candidate for treating PEDV infection.

PMID 42466851
Read full article →
PubMedLuminescence : the journal of biological and chemical luminescence2026-07-16

Pioneering Novel, Green, White, and Blue Fluorescence-Based Platforms for Sustainable and Concurrent Monitoring of Ciprofloxacin With Celecoxib or Itopride in Biological Matrices.

Barakat Neamat T NT, El-Aziz Heba Abd HA, Eid Manal I MI, Ibrahim Fawzia A FA

Two innovative spectrofluorimetric techniques were developed for the first time to enable simultaneous quantification of ciprofloxacin hydrochloride in binary mixtures with either celecoxib or itopride hydrochloride in biological fluids. The first relied on synchronous spectrofluorimetry at a constant wavelength interval (Δλ = 100 nm), which effectively reduced spectral interference and allowed accurate estimation of celecoxib and ciprofloxacin hydrochloride at their zero-crossing points of 276 and 328 nm, respectively. The second technique leveraged direct spectrofluorimetric measurement of ciprofloxacin hydrochloride and itopride hydrochloride mixture, using excitation at 258 nm that yielded two discrete emission peaks at 351 nm for ITH and 441 nm for CPN. Both methods demonstrated remarkable sensitivity and selectivity, achieving excellent linearity (r = 0.9999) across broad ranges of (0.05-3.0 μg/mL and 0.05-5.0 μg/mL for ciprofloxacin hydrochloride and celecoxib, respectively, and 0.07-4.0 μg/mL for ciprofloxacin hydrochloride and 0.04-9.0 μg/mL for itopride hydrochloride. Comprehensive greenness assessment was performed, which confirmed their low environmental burden. Moreover, whiteness and blueness evaluations highlighted the favorable integration of analytical efficiency with sustainability principles. The proposed strategies combine rapidity, high sensitivity, and environmental safety, providing reliable alternatives for routine quality control of pharmaceutical formulations and accurate determination of CPN mixtures in biological matrices.

PMID 42458825
Read full article →
PubMedCureus2026-07-16

From Dermographism in Bracelets to Dermatophytosis in Circles: The First Case of Tinea Imbricata Diagnosed in Morocco.

Mansar Nouha N, Naciri Nada N, El Mezouari El Mustapha EM, Moutaj Redouane R

Tinea imbricata is a chronic superficial dermatophytosis caused by the anthropophilic dermatophyte Trichophyton concentricum and is typically characterized by pruritic concentric annular scaly lesions. The disease is endemic to regions of Southeast Asia, the Pacific Islands, and Latin America and remains exceptionally rare in North Africa. We report the first documented case of tinea imbricata diagnosed in Morocco in a 38-year-old Pakistani man residing in Louisiana, USA, who developed characteristic skin lesions while staying in Morocco. The lesions appeared as intensely pruritic concentric plaques involving the inner thighs. Direct microscopic examination and fungal culture findings were highly suggestive of Trichophyton concentricum as the causative organism. Initial treatment with oral terbinafine combined with topical antifungal therapy resulted in only partial clinical improvement. Complete remission was achieved after switching to oral itraconazole associated with topical antifungal treatment. This case highlights the importance of considering imported tropical dermatophytoses even in non-endemic settings.

PMID 42460170
Read full article →
PubMedCurrent microbiology2026-07-16

In Vitro Antifungal Evaluation, GC-MS Profiling, and Molecular Docking of Eruca sativa Oil, Clove Oil, and Fusarium chlamydosporum Extract Against the Dermatophyte Trichophyton interdigitale.

Elsaba Yasmin M YM, Osman Mohamed E ME, Ahmed Ayman F AF, Hegazy Mona Mohamed Darwish MMD et al.

Antifungal drug resistance in Trichophyton interdigitale reinforces the need for new drugs with multiple targets. The antifungal activity of Eruca sativa seed oil, clove oil, and ethanolic extract of Fusarium chlamydosporum was evaluated against a clinically isolated T. interdigitale Accession No. ON564615 that was later molecularly confirmed. The Gas Chromatography Mass Spectrometry GC MS method was used to profile the bioactive constituents. In order to analyze their high affinity binding to several important enzymes of the ergosterol pathway such as squalene epoxidase ERG1, C 24 sterol methyltransferase ERG6, and lanosterol 14α demethylase ERG11, their multi target effects were systematically analyzed using integrated molecular docking simulations. In this study E. sativa oil exhibited significant activity yielding an inhibition zone of 57.7 mm and an MIC of 6.25 mg/mL. The effect of F. chlamydosporum extract in combination with clove oil was remarkably strong showing 72.67 mm of inhibition which is higher than that of the first line drug terbinafine 61 mm. In addition the presence of eugenol in clove oil and of ethyl iso allocholate in E. sativa and the fungal extracts was detected by GC MS analysis. The present data are limited to in vitro and in silico testing of a single clinical isolate; however the findings are highly suggestive of the potential of using E. sativa oil and or certain specific combinations of fungal and plant extracts as promising multi target antifungals. In vivo studies are required in the future to fully confirm their clinical translatability against resistant dermatophytosis.

PMID 42461428
Read full article →
PubMedAnnals of hematology2026-07-16

Breast cancer risk in female survivors of Hodgkin lymphoma after exposure to non-pegylated liposomal doxorubicin at young adult and adult age: the first real-life series from Southern Italy cancer centers.

Picardi Marco M, Vincenzi Annamaria A, Giordano Claudia C, Pugliese Novella N et al.

Studies in female Hodgkin lymphoma (HL) survivors have shown that doxorubicin hydrochloride exposure at young adult and adult (YA&A) age is associated with an increased risk of breast cancer (BC) regardless of chest-radiotherapy (c-RT). Although non-pegylated liposomal doxorubicin (NPLD)-based regimens have shown efficacy and safety in the treatment of lymphoma, the association between NPLD exposure and BC risk has not been examined in HL survivors. We assessed standardized incidence ratio (SIR) and absolute excess risk (AER) of BC in a cohort of 100 female ≥ 5-year HL survivors treated between 18 and 60 years of age with NPLD-based regimen in tertiary hospitals in southern Italy between 2009 and 2020. The median cumulative liposomal doxorubicin dose was 290 mg/m²; c-RT was administered to 20% of patients. After a median follow-up of 10 years (interquartile range, 8-11 years), no women had developed BC. Compared with the Italian general population, the SIR was 0.00 (95% confidence interval, 0.00-4.29); the standardized ratio was 86.5 per 100,000 person per year according to the AIRTUM (Associazione Italiana Registri Tumori) Working Group data for women aged between 18 and 60 years. In our series, the AER was - 8.87 per 10,000 person per year. Based on data derived from the pooled summary rate of literature, HL survivors treated with doxorubicin hydrochloride-including regimens at YA&A age had an incidence rate of BC of 1.6% at 10-year median follow-up. These data, if validated in largest datasets with longer follow-up, suggest that treatment with NPLD could be not associated with increased BC risk in HL survivors, unlike conventional doxorubicin. Our findings provide a rationale for evaluating NPLD-based frontline therapy in prospective studies of YA&A patients with newly diagnosed HL.

PMID 42461398
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about terbinafine hydrochloride